Pliant Therapeutics to Present Research in Phoenix

The company will unveil new data on its solid tumor treatment at the Society for Immunotherapy of Cancer annual meeting.

Updated on Oct. 29, 2026 in Biotech

Isometric editorial illustration of a complex molecular structure, representing the structural research in cancer immunotherapy presented at the medical conference. — Pliant Therapeutics will present clinical research data on its therapeutic candidate PLN-101095 during the Society for Immunotherapy of Cancer annual meeting in Phoenix. AI Illustration. Upload story photo >

Live Poll

Do clinical research trial updates indicate real progress in treating advanced solid tumors?

Pliant Therapeutics will present two research studies at the 41st Annual Meeting of the Society for Immunotherapy of Cancer in Phoenix from November 4 to 8, 2026. The presentations focus on the company's therapeutic candidate PLN-101095 and its role in cancer immunotherapy.

Why it matters

These presentations provide clinical insights into the safety and antitumor activity of PLN-101095, a dual-selective integrin inhibitor being studied for solid tumor patients. Sharing these findings at a major conference helps advance the broader scientific understanding of integrin targeting combined with immune checkpoint inhibition.

The FORTIFY clinical trial evaluates PLN-101095 using a dose-escalation design where participants receive 1,000 mg twice daily for 14 days before the addition of pembrolizumab. The research explores the drug as a dual-selective inhibitor of αvβ8 and αvβ1 integrins.

The players

Pliant Therapeutics

This clinical-stage biotechnology company is headquartered in South San Francisco, California.

Nika Rajabian

This researcher is a presenter representing Pliant Therapeutics at the upcoming annual meeting.

Martin L. Decaris

This scientist is a presenter who will share specific data regarding the company's clinical trial biomarkers.

The details

Nika Rajabian will present a poster regarding integrin targeting and immune checkpoint inhibition, while Martin L. Decaris will share findings on plasma biomarkers and the FORTIFY trial. This research remains central to the ongoing investigation of the candidate under identifier NCT06270706.

The 41st Annual Meeting of the Society for Immunotherapy of Cancer runs from November 4 to 8, 2026.
Nika Rajabian is scheduled to present a poster on November 6, 2026.
Martin L. Decaris is scheduled to present a poster on November 7, 2026.

The Tech Race

This research follows the established protocol and expansion design of the FORTIFY trial to further define the potential of PLN-101095. The work represents a shift toward more precise integrin targeting as the industry moves beyond traditional checkpoint inhibitors.

These findings inform the future availability of new treatment options for patients with solid tumors. The data could eventually influence how clinicians prescribe combination therapies, though the drug remains in the experimental phase of clinical testing.

The takeaway

Advancements in integrin inhibition represent a growing area of focus for pharmaceutical companies seeking to improve solid tumor outcomes. Patients and providers should monitor the progress of clinical trials like FORTIFY to stay informed on potential new treatment pathways.